Close Menu

This article has been updated to include a statement from the Broad Institute.

NEW YORK (GenomeWeb) – CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences, and ERS Genomics said Tuesday that the co-owners of intellectual property relating to CRISPR-Cas9 gene editing technology and licensed by these firms are seeking reversal of a decision by the US Patent and Trademark Office's Patent Trial and Appeal Board in a patent interference proceeding. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new study catalogues the genome and evolutionary history of the oak family, UPI reports.

Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.

A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.

In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.